Payment overview · 2025
General Payments
$3,881.87
122 reported records · 22 companies
Healthcare provider profile · identity verified
Herman Hasselkus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · AURORA, CO · NPI 1053481382
Verified facts
What the public records show
CMS Open Payments records show Herman Hasselkus, M.D. received $3,881.87 in general payments during 2025 across 122 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,158.40 | 29.8% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $600.51 | 15.5% | 20 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $486.23 | 12.5% | 26 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $381.76 | 9.8% | 11 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $255.14 | 6.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $156.42 | 4.0% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $124.80 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $121.29 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $85.59 | 2.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.92 | 2.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.90 | 2.0% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $59.74 | 1.5% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.63 | 1.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.54 | 1.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.38 | 1.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.20 | 0.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $31.42 | 0.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.95 | 0.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.95 | 0.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.85 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.82 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.43 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,881.87 | 122 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $453.30 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $431.40 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $419.07 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $335.23 | 23 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $323.71 | 24 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $269.19 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $256.96 | 10 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $255.14 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $169.11 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $156.42 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $134.36 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $121.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $85.59 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.92 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.90 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.74 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $34.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.20 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.92 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $27.95 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 368 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 90 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
368 | 105 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
138 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
63 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 983 | 320 |
| Metformin Hcl | Metformin Hcl | 380 | 159 |
| Farxiga | Dapagliflozin Propanediol | 368 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 117 |
| Lisinopril | Lisinopril | 314 | 104 |
| Losartan Potassium | Losartan Potassium | 281 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 86 |
| Omeprazole | Omeprazole | 229 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 80 |
| Gabapentin | Gabapentin | 195 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 178 | 47 |
| Tramadol Hcl | Tramadol Hcl | 161 | 47 |
| Furosemide | Furosemide | 142 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 142 | 48 |
| Ozempic | Semaglutide | 138 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 84 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 134 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 47 |
| Jardiance | Empagliflozin | 126 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 41 |
| Metformin Hcl Er | Metformin Hcl | 122 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 18 |
| Montelukast Sodium | Montelukast Sodium | 114 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 108 | 44 |
| Ezetimibe | Ezetimibe | 107 | 53 |
| Potassium Chloride | Potassium Chloride | 102 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 49 |
| Trazodone Hcl | Trazodone Hcl | 96 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 60 |
| Sertraline Hcl | Sertraline Hcl | 92 | 41 |
| Mounjaro | Tirzepatide | 90 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 19 |
| Carvedilol | Carvedilol | 85 | 26 |
| Eliquis | Apixaban | 84 | 25 |
| Celecoxib | Celecoxib | 83 | 35 |
| Pregabalin | Pregabalin | 83 | 28 |
| Repatha Sureclick | Evolocumab | 81 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 21 |
| Alendronate Sodium | Alendronate Sodium | 76 | 31 |
| Allopurinol | Allopurinol | 73 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 68 | 26 |
| Donepezil Hcl | Donepezil Hcl | 67 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 25 |
| Rybelsus | Semaglutide | 63 | 21 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 62 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 21 |
| Lorazepam | Lorazepam | 53 | suppressed |
| Finasteride | Finasteride | 51 | 20 |
| Doxepin Hcl | Doxepin Hcl | 48 | 28 |
| Atenolol | Atenolol | 47 | 12 |
| Glimepiride | Glimepiride | 47 | 19 |
| Trulicity | Dulaglutide | 47 | 14 |
| Azithromycin | Azithromycin | 46 | 39 |
| Meclizine Hcl | Meclizine Hcl | 46 | 30 |
| Xarelto | Rivaroxaban | 46 | 17 |
| Meloxicam | Meloxicam | 44 | 26 |
| Prednisone | Prednisone | 44 | 30 |
| Ibuprofen | Ibuprofen | 43 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Nabumetone | Nabumetone | 39 | 21 |
| Amoxicillin | Amoxicillin | 37 | 33 |
| Mirtazapine | Mirtazapine | 36 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 16 |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Dutasteride | Dutasteride | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 19 |
| Spironolactone | Spironolactone | 29 | 13 |
| Temazepam | Temazepam | 29 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 25 |
| Promethazine Hcl | Promethazine Hcl | 28 | 14 |
| Sucralfate | Sucralfate | 28 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 16 |
| Gemtesa | Vibegron | 27 | 12 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Glipizide | Glipizide | 25 | 11 |
| Linzess | Linaclotide | 25 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Valacyclovir | Valacyclovir Hcl | 24 | 17 |
| Baclofen | Baclofen | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | 13 |
| Colchicine | Colchicine | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 19 | suppressed |
| Prolia | Denosumab | 19 | 15 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | 11 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,881.87 · 122 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BOTOX, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, REZDIFFRA, SHINGRIX, SPRAVATO, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error